...
机译:使用5-α还原酶抑制剂来管理良性前列腺增生和全导致死亡率的风险
Department of Medicine and Epidemiology University of Michigan;
Real World Evidence &
Epidemiology GlaxoSmithKline;
Department of Research and Evaluation Kaiser Permanente Southern California;
Division of Research Kaiser Permanente Northern California;
Center for Health Research Kaiser Permanente Northwest;
Institute for Health Research Kaiser Permanente Colorado;
Real World Evidence Janssen;
Department of Biostatistical Science Wake Forest University;
Department of Research and Evaluation Kaiser Permanente Southern California;
Division of Research Kaiser Permanente Northern California;
Institute for Transformative Medicine Temple University and Visiting Scholar Institute of Medicine;
Department of Research and Evaluation Kaiser Permanente Southern California;
Alpha-blockers; Benign prostatic hyperplasia; 5 Alpha-reductase inhibitors; Lower urinary tract symptoms; Mortality;
机译:使用5-α还原酶抑制剂来管理良性前列腺增生和全导致死亡率的风险
机译:5-α还原酶抑制剂和良性前列腺增生治疗男性前列腺癌死亡率的风险。
机译:5-α还原酶抑制剂和良性前列腺增生治疗男性前列腺癌死亡的风险
机译:经皮热疗对良性前列腺增生症的治疗方案
机译:良性前列腺增生:代谢异常的作用以及与前列腺癌风险的关系。
机译:用5-α还原酶抑制剂(5ARIS)治疗具有良性前列腺增生的男性静脉血栓栓塞(VTE)的风险。
机译:MP04-02 5-Alpha还原酶抑制剂和用于良性前列腺增生治疗男性前列腺癌死亡的风险